Source: Annual Congress 2011 - Lung development and neoplasia
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Bargagli, C. Olivieri, C. Landi, B. Magi, D. Bennett, N. Bianchi, A. Perrone, A. Fossi, P. Rottoli (Sienna, Italy). Serum amyloid A as a potential biomarker of sarcoidosis. Eur Respir J 2011; 38: Suppl. 55, 3807

Member's Comments

No comment yet.

Related content which might interest you: The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis? Source: International Congress 2017 – Rare diseases Year: 2017 Serum endostatin as a genetically-influenced biomarker in PAH Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019 Serum C-reactive protein concentrations in patients with sarcoidosis: can be taken this simple test as an activation marker in sarcoidosis? Source: Eur Respir J 2004; 24: Suppl. 48, 712s Year: 2004 Elevated circulating concentrations of adiponectin in sarcoidosis – a new marker of disease? Source: Annual Congress 2006 - Clinical features and disease markers of sarcoidosis Year: 2006 The serum YKL-40 is a useful biomarker for asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017 Visfatin as a possible serum biomarker in COPD Source: International Congress 2019 – Crosstalk in chronic pulmonary diseases Year: 2019 Serum KL-6 as a marker of disease progression in SSc-ILD Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Serum neopterin and IL-6 as biomarkers in patients with COPD. Source: International Congress 2017 – Novel molecular and genetic targets in COPD Year: 2017 Circulating total leptin as a diagnostic and prognostic biomarker in sepsis Source: International Congress 2019 – ECMO, ECCO2R and other rescue therapies in acute respiratory failure Year: 2019 Serum markers of acute sarcoidosis. Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases Year: 2020 Study of angiotensin-converting enzyme, serum amyloid A, soluble interleukin-2 receptor, lysozyme and KL-6 in serum as diagnostic markers in pulmonary sarcoidosis Source: Annual Congress 2007 - Sarcoidosis: various aspects Year: 2007 Plasma circulating miRNAs as diagnostic and prognostic biomarkers in alpha-1 antitrypsin deficiency. Source: International Congress 2019 – Crosstalk in chronic pulmonary diseases Year: 2019 Serum napsin A is a novel diagnostic and monitoring marker for interstitial lung disease Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011 Serum markers of IPF Source: Research Seminar 2004 - Genotyping and Phenotyping of Diffuse Parenchymal Lung Diseases Year: 2004 KL-6 is a useful serum biomarker for early detection of interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Evaluation of CCL18 serum levels and genetic variant as prognostic biomarkers in SSc-ILD Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Serum CC16 is a potential predictor for IPF diagnosis and prognosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Serum KL-6, SP-D and MMP-2 as diagnostic biomarkers in asbestosis and silicosis Source: International Congress 2017 – Silicosis has not gone away Year: 2017 Serum levels of chitotriosidase in pulmunary sarcoidosis Source: Annual Congress 2008 - COPD and other environment-related lung diseases Year: 2008 Investigation of possible role of serum fibulin as biomarker of COPD. Source: Virtual Congress 2020 – Mechanistic insight into lung injury and repair Year: 2020